Recent Updates
Recently added Catalysts
AMRN Positive Sentiment Score: 70/100

Amarin to Present at Cowen's 43rd Annual Health Care Conference

Key Takeaway: Amarin Corporation plc announced its participation in the Cowen Annual Health Care Conference taking place from March 6 to March 8, 2023, in Boston. The company's president and CEO, Karim Mikhail, is scheduled to present on March 8 at 1:30 p.m. ET. This presentation underscores Amarin's commitment to advancing cardiovascular disease management through innovative therapies. The event will be available via live webcast and archived on the company's investor relations website for broader access.

Market Sentiment Analysis

POSITIVE FACTORS

  • Amarin is participating in a prestigious health care conference.
  • The conference offers a platform to showcase Amarin's innovations.
  • The company is committed to advancing cardiovascular treatment options.

Full Press Release Details

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Cowen Annual Health Care Conference.
Cowen Annual Health Care Conference (March 6 – 8th, 2023; Boston)
Date/Time: Wednesday, March 8, 2023; 1:30 p.m. ET
The conference presentation will be webcast live and archived on the Company’s website in the Investor Relations section under Events and Presentations.
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Amarin Corporation plc
IR@amarincorp.com (investor inquiries)
Amarin Corporation plc
PR@amarincorp.com (media inquiries)

Frequently Asked Questions

When is Amarin's presentation at the Cowen Conference?

Amarin's presentation is on March 8, 2023, at 1:30 p.m. ET.

Where can I watch Amarin's conference presentation?

The presentation will be available via webcast on Amarin's website.

What is Amarin's focus in the pharmaceutical sector?

Amarin focuses on cardiovascular disease management and scientific research.

How can investors stay updated on Amarin's information?

Investors can check Amarin's website and investor relations channels regularly.

What are Amarin's contact emails for inquiries?

For investor inquiries, email IR@amarincorp.com and for media, PR@amarincorp.com.

Last updated: Feb 22, 2023